Welcome to our dedicated page for Kyverna Therapeutics news (Ticker: KYTX), a resource for investors and traders seeking the latest updates and insights on Kyverna Therapeutics stock.
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on developing CD19-targeting CAR T-cell therapies for autoimmune diseases, and its news flow reflects this focus. Company updates frequently highlight progress with its lead autologous CAR T-cell therapy candidate, mivocabtagene autoleucel (miv-cel, KYV-101), in B-cell-driven autoimmune conditions.
Visitors to this KYTX news page can review announcements on Kyverna’s registrational trials in stiff person syndrome (SPS) and generalized myasthenia gravis (gMG). Recent press releases describe positive topline data from the KYSA-8 registrational Phase 2 trial in SPS and interim Phase 2 data from the KYSA-6 registrational Phase 2/3 trial in gMG, including reported effects on disability, mobility, and disease activity scores, as well as safety outcomes such as the absence of high-grade cytokine release syndrome or ICANS in the reported datasets.
News items also cover Kyverna’s broader development and financing activities. These include business updates and quarterly financial results, a loan facility with Oxford Finance LLC, and public equity offerings under an effective shelf registration statement on Form S-3. Additional releases describe investigator-initiated trials in multiple sclerosis and rheumatoid arthritis, Phase 1/2 trials in lupus nephritis, and the advancement of KYV-102, which the company characterizes as using a whole blood rapid manufacturing process.
Investors and followers of KYTX can use this page to track Kyverna’s press releases on clinical milestones, regulatory plans such as an anticipated BLA submission for SPS, corporate presentations at healthcare conferences, leadership and governance changes, and capital-raising transactions. Checking this feed provides a consolidated view of how the company reports its progress in autoimmune CAR T-cell therapy and related corporate developments.
Kyverna Therapeutics announced three key leadership appointments to support its next growth phase in developing cell therapies for autoimmune diseases. Dan Maziasz joins as Chief Business Officer, bringing 25 years of experience from companies like Atara Biotherapeutics and Kite Pharma. Cara Bauer becomes Chief Human Resources Officer, with over 25 years of global HR leadership experience, notably at Kite and Netflix. Tracy Rossin joins as SVP of Corporate Affairs, Communications and Investor Relations, bringing 20 years of strategic communications experience from Kite and AstraZeneca.
As part of his appointment, Maziasz received an inducement grant of options to purchase 350,000 shares at $4.86 per share, vesting over four years with 25% vesting after one year and the remainder monthly.
Kyverna Therapeutics presented updated clinical data for KYV-101, their CD19 CAR T-cell therapy for lupus nephritis (LN) treatment. The data shows sustained efficacy and durability in patients treated with the target dose of 1×108 CD19 CAR T cells, with four out of six patients having at least six months of follow-up. Key findings demonstrate deep B cell depletion, immune system reset, stabilized eGFR, preserved kidney function, and improved SLE activity. The treatment allowed elimination of immunosuppressants and reduction of glucocorticoids while maintaining a manageable safety profile with no high-grade CRS or ICANS observed.
Kyverna Therapeutics reported Q3 2024 financial results and business updates. The company appointed Warner Biddle as CEO and made multiple key leadership appointments. They presented clinical data for KYV-101 in various autoimmune conditions at ECTRIMS and plan to share updated lupus nephritis data at ACR Convergence 2024.
The company reported a net loss of $34.3 million ($0.80 per share) for Q3 2024, compared to $15.5 million in Q3 2023. Cash position remains strong at $321.6 million as of September 30, 2024. Net cash used in operations was $77.2 million for the first nine months of 2024.
Kyverna Therapeutics, Inc. (KYTX) has appointed Mert Aktar as an independent director to its Board of Directors. Mr. Aktar brings over two decades of biopharmaceutical experience, combining technical leadership in cell and gene therapy with a proven track record in corporate development. He currently serves as CEO of Receptive Bio and holds board positions with UCLA Technology Development Group and ReAlta Life Sciences.
Previously, Mr. Aktar was Senior Vice President and Global Head of Corporate Development & Strategy at Kite Pharma, where he played a key role in establishing Kite's global leadership in cell therapy. He also held senior leadership positions at various biotech and large pharma organizations, including Shire, where he facilitated multi-billion-dollar transactions and led large-scale manufacturing operations.
Kyverna's CEO, Warner Biddle, expressed confidence that Mr. Aktar's strategic experience and technical expertise in cell therapy will be invaluable as the company advances KYV-101 into later stages of development and builds on its CAR T leadership in autoimmune diseases.
Kyverna Therapeutics presented patient data at ECTRIMS 2024, showcasing the potential of KYV-101 for treating neuroinflammatory diseases. The company shared case reports from 11 patients with stiff-person syndrome, myasthenia gravis, and multiple sclerosis, demonstrating initial efficacy and safety of KYV-101. Key biomarkers indicate its potential to durably modify neuroinflammatory diseases through immune system reset.
Highlights include:
- Improved mobility and reduced autoantibody titers in stiff-person syndrome patients
- Sustained disease control in myasthenia gravis patients
- Significant reduction in oligoclonal bands in multiple sclerosis patients
- No severe CRS or ICANS observed across 41 treated patients
Kyverna also presented posters on the design and methods of its clinical trials for KYV-101 in neuroinflammatory diseases.
Kyverna Therapeutics (KYTX) announced key leadership changes. Warner Biddle has been appointed as the new Chief Executive Officer and Board member, replacing Peter Maag. Biddle brings over 30 years of experience in commercial and franchise leadership, including successful CAR T therapy launches at Kite Pharma. Christi Shaw, a seasoned life sciences executive, joins the Board of Directors, succeeding Brian Kotzin.
These appointments aim to strengthen Kyverna's leadership as it advances its CAR T cell therapies for autoimmune diseases. The company's lead candidate, KYV-101, is progressing into later development stages. Biddle's experience in commercializing cell therapies and Shaw's broad industry expertise are expected to guide Kyverna through its next growth phase, focusing on market preparation and expansion in the autoimmune disease space.
Kyverna Therapeutics (KYTX), a clinical-stage biopharmaceutical company focusing on cell therapies for autoimmune diseases, has announced its participation in three major investor conferences in September 2024:
- Morgan Stanley Global Healthcare Conference in New York, NY on September 4
- Wells Fargo Healthcare Conference in Boston, MA on September 5
- Cantor Global Healthcare Conference in New York, NY on September 17
At each event, Kyverna executives will engage in fireside chats and host investor meetings. This series of appearances provides significant opportunities for the company to showcase its progress and connect with potential investors.
Kyverna Therapeutics (Nasdaq: KYTX) reported its Q2 2024 financial results and business updates. Key highlights include:
- Actively recruiting for clinical trials in neurology and rheumatology with KYV-101
- No severe ICANS or CRS reported in first 36 autoimmune disease patients treated with KYV-101
- Received FDA RMAT Designations for KYV-101 in Stiff-Person Syndrome and Myasthenia Gravis
- Reported first KYV-101 patient disease-free at 1 year post-treatment
- 100% manufacturing success rate for KYV-101
- Net loss of $28.8 million for Q2 2024
- $346.2 million in cash and equivalents as of June 30, 2024
Kyverna continues to advance its CAR T-cell therapies for autoimmune diseases, with promising initial safety and efficacy data for KYV-101.
Kyverna Therapeutics (KYTX) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for KYV-101, its autologous CD19 CAR T-cell therapy for progressive myasthenia gravis. This designation was based on positive clinical outcomes from patients treated in Germany under a named-patient program. The RMAT status allows Kyverna to benefit from expedited meetings and senior FDA leadership involvement throughout KYV-101's development cycle.
Dr. Srikanth Muppidi, a principal investigator in the KYSA-6 trial, emphasized that this designation highlights the FDA's interest in potentially transformative therapies for severe autoimmune diseases. Kyverna's CEO, Peter Maag, expressed satisfaction with the company's scientific rapport with the FDA and hopes this rigorous approach will benefit patients most in need.
Kyverna Therapeutics (KYTX) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for KYV-101, its autologous CD19 CAR T-cell therapy, in treating refractory stiff-person syndrome. This designation, based on positive clinical outcomes in Germany, allows Kyverna to receive expert guidance on efficient drug development and use of surrogate endpoints from senior FDA officials. The company is set to begin its sponsored trial, KYSA-8, which could potentially revolutionize SPS treatment by offering a durable, immunosuppressant-free remission through an immunological reset of the patient's immune system.